AEON Biopharma
AEON
AEON
21 hedge funds and large institutions have $20.5M invested in AEON Biopharma in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 13 reducing their positions, and 69 closing their positions.
New
Increased
Maintained
Reduced
Closed
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less capital invested
Capital invested by funds: $ → $
93% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 69
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Holders
21
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$1.32M | |
| 2 | +$549K | |
| 3 | +$162K | |
| 4 |
CCM
CAAS Capital Management
New York
|
+$120K |
| 5 |
FTUS
Flow Traders U.S.
New York
|
+$108K |
Top Sellers
| 1 | -$13.3M | |
| 2 | -$12.8M | |
| 3 | -$12.6M | |
| 4 |
ECP
Empyrean Capital Partners
Los Angeles,
California
|
-$12.2M |
| 5 |
D.E. Shaw & Co
New York
|
-$11.9M |